Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest/Arousal Disorder

/PRNewswire/ -- Freya Pharma Solutions, a pharmaceutical company dedicated to developing effective pharmaceutical therapies for women diagnosed with Female...

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,United States ,American ,Marcel Wijma ,Freya Pharma ,Us Clinical Development Program Of Lybrido ,Drug Administration ,Freya Pharma Solutions ,American Psychiatric Association ,Lifespring Life Sciences Communication ,Female Sexual Disorders ,Development Program ,Female Sexual ,Arousal Disorder ,European Medicines ,Scientific Advisory Board ,Marketing Authorization Application ,Chief Medical Officer ,Sexual Desire Disorder ,Statistical Manual ,Mental Disorders ,Pharma Solutions ,Chief Executive ,Spring Life Sciences Communication ,